Abstract:We report a 54-year-old man with progressive generalized muscle atrophy and ophthalmoparesis in the terminal stage. He was well until 44 years of age (1982) when he noted weakness in his right hand and muscle atrophy; in May of 1985, he noted weakness in his left hand and in both legs. His weakness had become progressively worse, and he became unable to walk in November of 1985. He noted dysarthria one month later, and dysphagia in March of 1986. His difficulty in swallowing had also become worse; he regurgitated foods into the trachea in September of that year, and he developed a low grade fever on the same day. He was admitted to our service on September 24, 1987. On physical examination, general findings were unremarkable, except for low grade fever (37.3 degrees C). On neurologic examination, he was alert and mentally sound. He had normal vision and visual fields; ocular movements were normal. He had moderate weakness in facial muscles, dysarthria, dysphagia, and atrophy in his tongue. He had marked generalized muscle atrophy with fasciculation. He was unable to stand or walk. His muscle strength was not more than 1/6 in any part. The lower extremities were spastic. Deep reflexes were exaggerated in both lower extremities but were normal in upper extremities. Sensation was intact. Laboratory examination was unremarkable, and so was the cranial CT scan. He was treated with nasogastric feeding. He was able to communicate smoothly using his eyes, but a restriction in the vertical gaze was noted in February of 1989. The range of ocular movement was better in the oculocephalic reflex compared with his spontaneous vertical eye movements. In April of 1990, his horizontal gaze also had become slow, and he was complicated by bronchial asthma. He was treated with 20 mg/day of prednisolone; after the institution of prednisolone, his horizontal eye movement showed much improvement. In the terminal stage, he was able to move his eyes only very slowly; vertical gaze was impossible. His subsequent course was complicated by respiratory tract infection and septicemia, and he expired on July 15, 1992. The patient was discussed in a neurological CPC, and the chief discussant arrived at the conclusion that this patient had amyotrophic lateral sclerosis with oculomotor paresis. Post-mortem examination revealed spongy change involving the posterior column and the posterior spinocerebellar tract, in addition to severe degenerative change in the upper and the lower motoneurons, which were consistent with amyotrophic lateral sclerosis.(ABSTRACT TRUNCATED AT 400 WORDS)

Subclinical spinal muscular atrophy in a 60-year-old man

[Spinal Muscular Atrophy with Open Bite: A Case Report].

The characteristics of spinal muscular atrophy in adults

Genotype-phenotype correlation in Chinese patients with spinal and bulbar muscular atrophy.

Rare homozygous disease-associated sequence variants in children with spinal muscular atrophy: A phenotypic description and review of the literature

Pyramidal signs in a Caucasian patient with spinal muscular atrophy: a case report.

Neurophysiological Evaluation of Autonomic Dysfunction in Spinal Muscular Atrophy: A Case-Control Study

Comprehensive profile and natural history of pediatric patients with spinal muscular atrophy: A large retrospective study from China

Spinal Muscular Atrophy Combined with Sporadic Olivopontocerebellar Atrophy

Spinal muscular atrophy with hypoplasia of the corpus callosum: a case report

A reassessment of spinal cord pathology in severe infantile spinal muscular atrophy

Diagnostic Journey of Korean Patients with Spinal Muscular Atrophy

Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy

EFFECTS OF TERAZOSIN ON GLYCEMIC CONTROL, CHOLESTEROL, AND MICROALBUMINURIA IN PATIENTS WITH NON‐INSULIN-DEPENDENT DIABETES MELLITUS AND HYPERTENSION

[Clinical characteristics and genetics functional analysis of two children with Spinal muscular atrophy]

Distinguishing Susac’s syndrome from multiple sclerosis

[A 54-year-old man with generalized muscle atrophy and oculomotor paresis]

Five patients with spinal muscular atrophy-progressive myoclonic epilepsy (SMA-PME): a novel pathogenic variant, treatment and review of the literature

Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil

Dysfunction of proprioceptive sensory synapses is a pathogenic event and therapeutic target in mice and humans with spinal muscular atrophy

Large Deletions Within the Spinal Muscular Atrophy Gene Region in A Patient with Spinal Muscular Atrophy Type 3